Want to see CRBP full AI Analyst Report?
Top Page
Corbus Pharmaceuticals
(NASDAQ:CRBP)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▼(-60.21% Downside)
Action:Reiterated
Date:10/15/26
The score is held down primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn) and strongly bearish technicals (price well below key moving averages with negative momentum). Positive corporate events around clinical progress provide upside optionality, but they are not yet enough to offset the current cash-burn profile and downtrend. Valuation is difficult to support with a negative P/E and no dividend yield.
Positive Factors
Clinical Progress in Oncology
CRB-701 has generated meaningful early efficacy data and progressed into a registrational study, improving the company’s clinical maturity. Successful execution could create a path toward a major oncology product, while the pembrolizumab combination expands the program’s strategic potential.
Negative Factors
Pre-Revenue Business Model
With no recurring product revenue, Corbus lacks an operating base that can internally fund research and development. Its value therefore depends heavily on clinical progress and eventual commercialization, making financial performance less predictable than that of an established drug company.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical Progress in Oncology
CRB-701 has generated meaningful early efficacy data and progressed into a registrational study, improving the company’s clinical maturity. Successful execution could create a path toward a major oncology product, while the pembrolizumab combination expands the program’s strategic potential.
Read all positive factors
Corbus Pharmaceuticals (CRBP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$78.33M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue GrowthN/A
EPS Growth-29.66%
CountryUS
Employees36
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.19
Shares Outstanding19,341,293
10 Day Avg. Volume835,538
30 Day Avg. Volume1,197,323
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.87
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.40K
Enterprise Value/Ebitda-0.67
Forecast
1Y Price Target
$36.67Price Target Upside224.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-5.43
Revenue Forecast (FY)$1.67M
Corbus Pharmaceuticals Business Overview & Revenue Model
Company Description
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the express...
How the Company Makes Money
Corbus Pharmaceuticals does not have a stable, product-based revenue model because it is a clinical-stage biopharmaceutical company and, to the extent publicly available information indicates, it does not currently market approved drugs that gener...
Corbus Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 881.71K |
| Gross Profit | -49.00K | 0.00 | -600.00K | 0.00 | -1.49M | -757.53K |
| EBITDA | -101.70M | -78.30M | -37.75M | -40.10M | -38.73M | -42.17M |
| Net Income | -101.90M | -78.54M | -40.21M | -44.60M | -55.83M | -45.55M |
Balance Sheet | ||||||
| Total Assets | 126.99M | 168.19M | 155.88M | 28.27M | 66.31M | 107.73M |
| Cash, Cash Equivalents and Short-Term Investments | 117.94M | 163.94M | 149.06M | 20.91M | 59.20M | 97.65M |
| Total Debt | 4.26M | 1.63M | 3.24M | 20.89M | 25.09M | 26.59M |
| Total Liabilities | 24.75M | 20.69M | 13.45M | 35.18M | 33.32M | 38.62M |
| Stockholders Equity | 102.24M | 147.50M | 142.43M | -6.91M | 32.99M | 69.11M |
Cash Flow | ||||||
| Free Cash Flow | -86.69M | -64.50M | -41.79M | -36.10B | -37.56M | -48.24M |
| Operating Cash Flow | -86.67M | -64.49M | -41.79M | -36.10B | -37.54M | -48.18M |
| Investing Cash Flow | 3.21M | -1.64M | -121.31M | 35.64B | 30.07M | -73.42M |
| Financing Cash Flow | 86.50M | 77.43M | 166.58M | -2.82B | -533.62K | 60.82M |
Corbus Pharmaceuticals Technical Analysis
Negative
11.31
Price Trends
7.77
Negative
8.30
Negative
8.72
Negative
Market Momentum
-1.01
Negative
18.67
Positive
6.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRBP, the sentiment is Negative. The current price of 11.31 is above the 20-day moving average (MA) of 5.26, above the 50-day MA of 7.77, and above the 200-day MA of 8.72, indicating a bearish trend. The MACD of -1.01 indicates Negative momentum. The RSI at 18.67 is Positive, neither overbought nor oversold. The STOCH value of 6.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CRBP.
Corbus Pharmaceuticals Risk Analysis
Corbus Pharmaceuticals disclosed 51 risk factors in its most recent earnings report. Corbus Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Corbus Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $162.20M | -2.54 | 152.56% | ― | -24.21% | 1.17% | |
45 Neutral | $77.99M | -4.80 | -41.15% | ― | -100.00% | 64.23% | |
44 Neutral | $78.33M | -0.63 | -87.05% | ― | ― | -29.66% | |
43 Neutral | $101.11M | -1.54 | -157.89% | ― | ― | 50.66% | |
43 Neutral | $58.69M | -0.21 | 108.75% | ― | 32.43% | 7.41% | |
42 Neutral | $39.19M | -1.68 | -53.14% | ― | ― | 54.84% |
* Healthcare Sector Average
CRBP
Corbus Pharmaceuticals
3.99
-13.02
-76.54%
IMUX
Immunic
7.28
-1.07
-12.80%
ALDX
Aldeyra Therapeutics
0.64
-4.59
-87.74%
EQ
Equillium
1.25
-0.12
-8.76%
GOSS
Gossamer Bio
9.15
-182.05
-95.21%
IPHA
Innate Pharma
1.46
-0.92
-38.66%
Corbus Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Corbus Pharmaceuticals Updates Oncology and Obesity Pipeline Strategy
Positive
Oct 15, 2026
On October 15, 2026, Corbus Pharmaceuticals updated its corporate presentation outlining clinical progress and milestones for its oncology and obesity pipeline. The new materials highlight promising Phase 1/2 data for CRB-701 in second-line oropha...
Business Operations and StrategyProduct-Related Announcements
Corbus Reports Positive Phase 1b Results for CRB-913
Positive
Sep 14, 2026
On September 14, 2026, Corbus Pharmaceuticals reported positive topline results from its CANYON-1 Phase 1b trial evaluating daily oral CRB-913 in 254 obese, non-diabetic adults across 15 U.S. sites. The 16-week, double-blind, placebo-controlled st...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Corbus Highlights Wider Loss and Strengthened Liquidity Position
Positive
Aug 6, 2026
Corbus Pharmaceuticals reported second-quarter 2026 results showing a net loss of $35.0 million, wider than the $17.7 million loss a year earlier, driven by a sharp rise in operating expenses to $36.2 million that included a $10.0 million mileston...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.